217 related articles for article (PubMed ID: 28606996)
1. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.
Smith MP; Rowling EJ; Miskolczi Z; Ferguson J; Spoerri L; Haass NK; Sloss O; McEntegart S; Arozarena I; von Kriegsheim A; Rodriguez J; Brunton H; Kmarashev J; Levesque MP; Dummer R; Frederick DT; Andrews MC; Cooper ZA; Flaherty KT; Wargo JA; Wellbrock C
EMBO Mol Med; 2017 Aug; 9(8):1011-1029. PubMed ID: 28606996
[TBL] [Abstract][Full Text] [Related]
2. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
3. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
4. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
5. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
[TBL] [Abstract][Full Text] [Related]
6. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.
Asundi J; Lacap JA; Clark S; Nannini M; Roth L; Polakis P
Mol Cancer Ther; 2014 Jun; 13(6):1599-610. PubMed ID: 24651527
[TBL] [Abstract][Full Text] [Related]
7. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Boshuizen J; Koopman LA; Krijgsman O; Shahrabi A; van den Heuvel EG; Ligtenberg MA; Vredevoogd DW; Kemper K; Kuilman T; Song JY; Pencheva N; Mortensen JT; Foppen MG; Rozeman EA; Blank CU; Janmaat ML; Satijn D; Breij ECW; Peeper DS; Parren PWHI
Nat Med; 2018 Feb; 24(2):203-212. PubMed ID: 29334371
[TBL] [Abstract][Full Text] [Related]
8. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
9. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
10. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
11. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA; Ngiow SF; Li M; Parmenter T; Mok S; Cass A; Haynes NM; Kinross K; Yagita H; Koya RC; Graeber TG; Ribas A; McArthur GA; Smyth MJ
J Clin Invest; 2013 Mar; 123(3):1371-81. PubMed ID: 23454771
[TBL] [Abstract][Full Text] [Related]
12. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
[TBL] [Abstract][Full Text] [Related]
13. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Russignan A; Spina C; Tamassia N; Cassaro A; Rigo A; Bagnato A; Rosanò L; Bonalumi A; Gottardi M; Zanatta L; Giacomazzi A; Scupoli MT; Tinelli M; Salvadori U; Mosna F; Zamò A; Cassatella MA; Vinante F; Tecchio C
Br J Haematol; 2017 Sep; 178(5):781-793. PubMed ID: 28597546
[TBL] [Abstract][Full Text] [Related]
15. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
16. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
18. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
20. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
